AGL 40.00 No Change ▼ 0.00 (0%)
AIRLINK 127.04 No Change ▼ 0.00 (0%)
BOP 6.67 No Change ▼ 0.00 (0%)
CNERGY 4.51 No Change ▼ 0.00 (0%)
DCL 8.55 No Change ▼ 0.00 (0%)
DFML 41.44 No Change ▼ 0.00 (0%)
DGKC 86.85 No Change ▼ 0.00 (0%)
FCCL 32.28 No Change ▼ 0.00 (0%)
FFBL 64.80 No Change ▼ 0.00 (0%)
FFL 10.25 No Change ▼ 0.00 (0%)
HUBC 109.57 No Change ▼ 0.00 (0%)
HUMNL 14.68 No Change ▼ 0.00 (0%)
KEL 5.05 No Change ▼ 0.00 (0%)
KOSM 7.46 No Change ▼ 0.00 (0%)
MLCF 41.38 No Change ▼ 0.00 (0%)
NBP 60.41 No Change ▼ 0.00 (0%)
OGDC 190.10 No Change ▼ 0.00 (0%)
PAEL 27.83 No Change ▼ 0.00 (0%)
PIBTL 7.83 No Change ▼ 0.00 (0%)
PPL 150.06 No Change ▼ 0.00 (0%)
PRL 26.88 No Change ▼ 0.00 (0%)
PTC 16.07 No Change ▼ 0.00 (0%)
SEARL 86.00 No Change ▼ 0.00 (0%)
TELE 7.71 No Change ▼ 0.00 (0%)
TOMCL 35.41 No Change ▼ 0.00 (0%)
TPLP 8.12 No Change ▼ 0.00 (0%)
TREET 16.41 No Change ▼ 0.00 (0%)
TRG 53.29 No Change ▼ 0.00 (0%)
UNITY 26.16 No Change ▼ 0.00 (0%)
WTL 1.26 No Change ▼ 0.00 (0%)
BR100 9,980 Increased By 95.8 (0.97%)
BR30 31,118 Increased By 518.2 (1.69%)
KSE100 94,024 Increased By 668.7 (0.72%)
KSE30 29,133 Increased By 201.9 (0.7%)

Britain's top share index hit a one-week closing high on Tuesday, after a drop in Spain's borrowing costs and encouraging data from Germany overshadowed fears over Europe's debt crisis. Short-term financing costs for Spain more than halved as banks lapped up debt at an auction, with much of the purchasing power said to have come from cut-rate loans from the European Central Bank (ECB).
---- Product pipeline problems knock drugmakers
This, alongside data showing a sharp rise in German business sentiment in December and US housing starts hitting a 19-month high in November, had a positive knock-on effect on risky assets such as banks. The UK banking sector recouped losses from the previous session when the British government backed proposals to force lenders to separate their retail and riskier investment arms.
But against the backdrop of light volume, with choppy short-term-driven trade likely to feature over the festive period, traders played down the significance of any moves. "There's not an awful lot of mileage in it - it's a trader's market, it's certainly not an investor's market," Michael Hewson, analyst at CMC Markets, said.
The UK benchmark FTSE 100 ended up 54.61 points, or 1 percent, at 5,419.60, its highest close since December 13, having shed 0.4 percent on Monday. It traded just 85 percent of its 90-day average volume. The FTSE 100 has fallen more than 8 percent this year. Andrew Bell, chief executive of the 1.1 billion pound ($1.73 billion) Witan Investment Trust, said that after derating, equity markets look attractive, especially relative to certain government bonds - provided meltdown in the European banking sector is avoided. He said: "2012 will turn out economically less bad than feared. Despite the immediate volatility risks, a shift towards looser monetary policy and the promotion of economic growth seems under way."
Bell added that there are well-articulated economic problems, but not the same risk to markets from forced deleveraging as occurred when hedge funds had to retrench after the collapse of investment bank Lehman Brothers in 2008. Stefan Angele, head of investment management at Swiss & Global Asset Management, which has around 80 billion Swiss francs ($86.08 billion) of funds under management, identified two crucial measures investors must adopt in 2012 given that economic and political uncertainties are running high.
"One is diversification to avoid counterparty and cluster risks, and the other is to ensure liquidity. Therefore, highly regulated and daily tradable investment vehicles like funds are attractive." Aggreko jumped 6.6 percent, the biggest blue chip riser, as Citigroup raised its earnings estimates for the temporary power provider by up to 12 percent, after the company on Monday nudged up 2011 profit forecasts.
Drugmakers came under pressure after AstraZeneca, Novartis and Sanofi reported product setbacks, underlining the difficulties of developing new medicines to make up for those going off-patent. With the weakest pipeline of its European peers, AstraZeneca, off 1.5 percent, was hit hardest by a double blow to treatments for cancer and depression. These triggered $381.5 million in charges and will push 2011 profits to the lower end of its forecast range. UK peer GlaxoSmithKline shed 0.3 percent.

Copyright Reuters, 2011

Comments

Comments are closed.